## **Christine Mateus**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4618201/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet, The, 2014, 384, 1109-1117.	13.7	1,588
2	Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nature Reviews Clinical Oncology, 2016, 13, 473-486.	27.6	831
3	Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors. European Journal of Cancer, 2019, 106, 106-114.	2.8	41
4	The 2016–2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study. European Journal of Cancer, 2020, 130, 39-50.	2.8	37
5	Arterial thrombosis and anti-PD-1 blockade. European Journal of Cancer, 2018, 91, 164-166.	2.8	26
6	Clinical outcomes after interstitial brachytherapy for early-stage nasal squamous cell carcinoma. Brachytherapy, 2017, 16, 1021-1027.	0.5	11
7	Post-shingles granulomatous dermatosis related to anti-programmed cell death 1. Immunotherapy, 2019, 11, 591-598.	2.0	9